查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715684

動物疫苗市場按產品類型、動物類型、疾病類型、給藥途徑和分銷管道分類－2025-2030 年全球預測

Animal Vaccines Market by Product, Animal Type, Disease Type, Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計獸用疫苗市場規模到 2024 年將達到 136.9 億美元，到 2025 年將達到 145.8 億美元，到 2030 年將達到 202.7 億美元，複合年成長率為 6.75%。

主要市場統計數據
基準年2024年 136.9億美元
預計2025年 145.8億美元
預測年份 2030 202.7億美元
複合年成長率（%） 6.75%

近年來，隨著人們對動物健康、食品安全和公共的認知不斷提高，獸用疫苗市場已成為全球衛生領域的重要領域。本報告深入探討了重塑該行業的演變趨勢、技術進步和戰略要務。科學、法規和市場需求的動態相互作用正在創造機會和挑戰，需要產品創新和對宿主生物學的敏銳理解。本介紹概述了關鍵主題，包括新型疫苗開發的作用、可靠的臨床數據的重要性以及影響市場採用的監管變化。疫苗輸送方法和製劑技術的不斷改進代表著變革時期，它正在重新定義獸醫和牲畜管理者如何進行預防性動物保健。深入研究這項綜合分析將闡明當前的實踐和未來的成長前景，幫助決策者根據新興市場訊號調整他們的策略。

全球獸用疫苗領域的特點是研發活動不斷增加、先進生物技術的整合和策略聯盟不斷加強。這些趨勢不僅刺激了創新，而且擴大了可用疫苗產品的範圍。當相關人員應對監管複雜性和競爭壓力時，了解這些變化對於使投資和營運重點與長期市場現實保持一致至關重要。

市場動態正在變革時期

獸用疫苗市場目前正處於變革時期，正在重塑產業動態並重新定義競爭格局。新技術為敏捷製造流程鋪平了道路，大大縮短了新型疫苗候選物的上市時間。基因工程和生物技術的關鍵進展凸顯了從傳統疫苗配方轉向 mRNA 和重組疫苗等創新方法的轉變。這種轉變不僅受到科學突破的推動，也受到強調功效、安全性和對疾病爆發的快速反應的不斷發展的法律規範的推動。

投資模式也發生了顯著變化，研發資金的增加使得獸醫疫苗接種方法更加個人化。產業相關人員目前正在利用數據分析和尖端診斷工具來評估不同動物物種的特定疾病特徵，從而找到更有針對性的疫苗解決方案。此外，數位健康平台的整合增強了監測疫苗接種後結果的能力，確保現實世界的療效支持臨床試驗的聲明。這種數位轉型正在創造一個持續反饋和自適應製造成為常態的環境，支援更具彈性和反應能力的供應鏈。

人們也越來越重視研究機構、生物製藥公司和獸醫師之間的合作。這種合作對於利用綜合專業知識將科學轉化為可行的市場解決方案至關重要。最終，向更技術化和數據化的行業轉變凸顯了長期改善動物健康、降低風險和實現更永續的疫苗市場的潛力。

深入了解動物疫苗的關鍵領域

對獸用疫苗市場的詳細分析揭示了多種細分策略，以了解該行業的多樣性和深度。特別值得注意的是產品細分，其涵蓋頻譜廣泛，包括去活化疫苗、減毒活病毒疫苗、mRNA疫苗、重組疫苗和次單位疫苗。這些分類代表了旨在最佳化不同物種免疫反應的技術進步和複雜的製造過程。產品配置的多樣化使相關人員能夠滿足特殊需求並針對其各自的動物健康挑戰制定解決方案。

此外，基於動物類型的細分提供了進一步的市場洞察。市場分為伴同性動物和牲畜，前者主要以貓和狗為代表，後者包括牛、家禽、羊和豬，每種動物都有不同的需求模式和監管要求。這種細分考慮了疫苗管理通訊協定的差異以及每個細分領域不同的經濟考量。例如，伴同性動物疫苗通常由飼主的偏好和預防性健康措施驅動，而牲畜疫苗必須符合嚴格的食品安全標準和生物安全法規。

基於疾病類型的分割透過關注細菌、真菌、寄生蟲和病毒感染增加了額外的粒度層。在此框架內，細菌感染疾病進一步分為梭菌病、大腸桿菌病、鉤端螺旋體病和巴氏桿菌症，而寄生蟲感染疾病則分為外寄生蟲和內寄生蟲。病毒感染疾病涵蓋幾種重要病原體，包括禽流感病毒、牛病毒性腹瀉病毒、口蹄疫病毒、新城疫病毒、豬隻繁殖與呼吸綜合症病毒和狂犬病毒。這些詳細的子類別顯示了特定病原體和疫苗反應之間的相互作用如何推動臨床、物流和金融領域的創新和市場區隔。

此外，對給藥途徑的分析可以深入了解疫苗設計的實際意義。疫苗分為注射疫苗和口服疫苗，注射疫苗的給藥途徑又分為肌肉注射、靜脈注射和皮下注射。這個詳細的市場區隔重點介紹了給藥途徑如何影響疫苗效力、依從性和整體市場滲透率。最後，分銷管道的細分，包括線上藥局、零售藥局和獸醫診所，凸顯了市場在維持傳統實體分銷網路的同時，正在適應數位轉型。這些細分策略結合起來可以提供一個全面的框架來了解市場趨勢，並幫助相關人員制定策略來有效滿足不同動物物種和疾病特徵的不同需求。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球通用感染疾病的盛行率不斷上升
      • 政府推動全球動物保健的舉措
    • 限制因素
      • 動物疫苗研究、開發和生產高成本
    • 機會
      • 與野生動物保護組織建立新的夥伴關係
      • 疫苗輸送創新增強了輸送能力並改善了動物的免疫反應
    • 任務
      • 圍繞動物疫苗的嚴格法規和核准程序
  • 市場區隔分析
    • 產品：減毒活病毒疫苗正日益成為防禦病原生物學複雜的疾病的首選方法。
    • 動物類型：寵物擁有量的增加增加了伴侶動物獸醫疫苗的重要性。
    • 疾病類型：抗病毒感染的動物疫苗需求不斷增加
    • 給藥途徑：肌肉注射疫苗由於能快速被血液吸收，因此變得越來越重要
    • 分銷管道：數位化平台的普及和便利性的提高推動了人們對網路藥局的偏好
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章動物疫苗市場（依產品）

  • 去活化疫苗
  • 減毒活疫苗
  • mRNA疫苗
  • 重組疫苗
  • 次單位疫苗

7. 動物疫苗市場（依動物類型）

  • 伴同性動物
    • 貓
    • 狗
  • 家畜
    • 牛
    • 家禽
    • 羊
    • 豬

第8章動物疫苗市場（依疾病類型）

  • 細菌感染疾病
    • 梭菌
    • 大腸桿菌
    • 鉤端螺旋體病
    • 巴氏桿菌
  • 黴菌感染疾病
  • 寄生蟲感染疾病
    • 體外寄生蟲
    • 體內寄生蟲
  • 病毒感染
    • 禽流感病毒
    • 牛病毒性腹瀉病毒（BVDV）
    • 口蹄疫病毒（FMDV）
    • 新城疫病毒
    • 豬繁殖與呼吸綜合症病毒（PRRSV）
    • 狂犬病毒

第9章動物疫苗市場（依給藥途徑）

  • 注射疫苗
    • 肌肉注射（IM）
    • 靜脈注射（IV）
    • 皮下（SC）
  • 口服疫苗

第 10 章動物疫苗市場（依通路）

  • 網路藥局
  • 零售藥局
  • 獸醫診所

第 11 章：美洲動物疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太動物疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲動物疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Biogenesis Bago SA
  • BioVaxys Technology Corporation
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma Private limited
  • Ceva Sante Animale
  • China Animal Husbandry Industry Co., Ltd.
  • Dalan Animal Health
  • Elanco Animal Health Inc.
  • Endovac Animal Health, LLC by Immvac Inc.
  • Hester Biosciences Limited
  • HIPRA, SA
  • Indian Immunologicals Limited
  • Kemin Industries, Inc.
  • Merck KGaA
  • Neogen Corporation
  • Phibro Animal Health Corporation
  • SAN Vet Holding GmbH
  • Sanofi SA
  • Seppic SA
  • Torigen Pharmaceuticals Inc.
  • Vaxxinova GmbH
  • VEROVACCiNES GmbH
  • Vetigenics, LLC
  • Vetoquinol SA
  • Virbac, Inc.
  • Zoetis Inc.
Product Code: MRR-ED54C46E8F03

The Animal Vaccines Market was valued at USD 13.69 billion in 2024 and is projected to grow to USD 14.58 billion in 2025, with a CAGR of 6.75%, reaching USD 20.27 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 13.69 billion
Estimated Year [2025] USD 14.58 billion
Forecast Year [2030] USD 20.27 billion
CAGR (%) 6.75%

In recent years, the animal vaccines market has emerged as a critical segment within the global health landscape, driven by growing awareness of animal health, food security, and public safety. This report provides an in-depth exploration of the evolving trends, technological advancements, and strategic imperatives that are reshaping this sector. The dynamic interplay between science, regulation, and market demand is creating opportunities and challenges that require a keen understanding of product innovations and host biology. This introduction sets the stage by outlining key themes including the role of novel vaccine development, the importance of robust clinical data, and the regulatory shifts that influence market adoption. The ongoing improvements in vaccine delivery methods and formulation techniques signify a transformative period that is redefining how veterinarians and livestock managers approach preventive animal health care. As we delve further into this comprehensive analysis, the discussion will illuminate both current practices and future growth prospects, thereby enabling decision-makers to align their strategies with emerging market signals.

The global animal vaccines landscape is characterized by ever-increasing research and development activities, integration of advanced biotechnologies, and strategic collaborations. These trends are not only fostering innovation but are also expanding the breadth of available vaccine products. As stakeholders navigate through regulatory complexities and competitive pressures, understanding these shifts becomes critical for aligning investment and operational priorities with long-term market realities.

Transformative Shifts in Market Dynamics

The animal vaccines market is currently experiencing transformative shifts that are reshaping industry dynamics and redefining competitive landscapes. Emerging technologies have paved the way for agile manufacturing processes and have significantly reduced the time-to-market for novel vaccine candidates. With pivotal advancements in genetic engineering and biotechnology, there is a marked transition from traditional vaccine formulations to innovative approaches such as mRNA and recombinant vaccines. This transformation is not solely driven by scientific breakthroughs but is also influenced by evolving regulatory frameworks that emphasize efficacy, safety, and rapid deployment in response to disease outbreaks.

A notable shift is occurring in the investment patterns, where increased funding in research and development is enabling a more personalized approach to animal immunization. Industry stakeholders are now leveraging data analytics and cutting-edge diagnostic tools to assess the unique disease profiles of different animal species, leading to more targeted vaccine solutions. Furthermore, the integration of digital health platforms has enhanced the ability to monitor post-vaccination outcomes, ensuring that real-world efficacy supports clinical trial claims. This digital transition is creating an environment where continuous feedback and adaptive manufacturing become the norm, thereby supporting a more resilient and responsive supply chain.

The emphasis on collaborative ventures between research institutions, biopharmaceutical companies, and veterinary practitioners has also intensified. Such alliances are critical in harnessing collective expertise to translate science into viable market solutions. Ultimately, the shift towards a more technologically empowered and data-informed industry underscores the potential for improved animal health outcomes, risk minimization, and a more sustainable vaccine market in the long run.

Key Segmentation Insights in Animal Vaccines

A detailed analysis of the animal vaccines market reveals multiple segmentation strategies that provide a rich understanding of the sector's diversity and depth. The product segmentation is particularly noteworthy as it encompasses a broad spectrum including inactivated vaccines, live attenuated vaccines, mRNA vaccines, recombinant vaccines, and subunit vaccines. These classifications illustrate the technological advancements and complex manufacturing processes designed to optimize immune responses across various species. This diversification in product profile enables stakeholders to address specialised needs and tailor solutions that align with distinct animal health challenges.

Moreover, segmentation based on animal type further refines market insights. The market distinguishes between companion animals and livestock, where the former, represented mainly by cats and dogs, and the latter, including cattle, poultry, sheep, and swine, drive distinct demand patterns and regulatory requirements. Such segmentation accounts for the variability in vaccine administration protocols and the differing economic considerations that underpin each segment. For instance, while companion animal vaccines are often driven by pet owner preferences and preventive health measures, vaccines for livestock animals must align with stringent food safety standards and biosecurity regulations.

The segmentation based on disease types adds another layer of granularity by focusing on bacterial infections, fungal infections, parasitic infections, and viral infections. Within this framework, bacterial infections are further divided into clostridial, Escherichia coli, leptospirosis, and pasteurella, while parasitic infections differentiate between ectoparasites and endoparasites. The viral segment covers several critical pathogens including avian influenza, bovine viral diarrhea virus, foot-and-mouth disease virus, Newcastle disease virus, porcine reproductive and respiratory syndrome virus, and rabies virus. These detailed sub-categories illustrate how the interplay between specific pathogens and vaccine responses drives innovation and market segmentation in clinical, logistical, and financial realms.

Additionally, analysis of the route of administration offers insights into the practical implications of vaccine design. The classifications include injectable and oral vaccines, with injectable routes being further delineated into intramuscular, intravenous, and subcutaneous methods. This detailed breakdown emphasizes how the route of administration can influence vaccine efficacy, compliance, and overall market penetration. Finally, the distribution channel segmentation, which includes online pharmacies, retail pharmacies, and veterinary clinics, underlines the market's adaptation to digital transformation while maintaining traditional physical distribution networks. Together, these segmentation strategies provide a comprehensive framework to understand market trends and enable stakeholders to craft strategies that effectively address the heterogeneous needs of diverse animal species and disease profiles.

Based on Product, market is studied across Inactivated Vaccines, Live Attenuated Vaccines, mRNA Vaccines, Recombinant Vaccines, and Subunit Vaccines.

Based on Animal Type, market is studied across Companion Animals and Livestock Animals. The Companion Animals is further studied across Cats and Dogs. The Livestock Animals is further studied across Cattle, Poultry, Sheep, and Swine.

Based on Disease Type, market is studied across Bacterial Infections, Fungal Infections, Parasitic Infections, and Viral Infections. The Bacterial Infections is further studied across Clostridial, E. Coli, Leptospirosis, and Pasteurella. The Parasitic Infections is further studied across Ectoparasites and Endoparasites. The Viral Infections is further studied across Avian Influenza Virus, Bovine Viral Diarrhea Virus (BVDV), Foot-and-Mouth Disease Virus (FMDV), Newcastle Disease Virus, Porcine Reproductive & Respiratory Syndrome Virus (PRRSV), and Rabies Virus.

Based on Route of Administration, market is studied across Injectable Vaccines and Oral Vaccines. The Injectable Vaccines is further studied across Intramuscular (IM), Intravenous (IV), and Subcutaneous (SC).

Based on Distribution Channel, market is studied across Online Pharmacies, Retail Pharmacies, and Veterinary Clinics.

Key Global Regional Insights

The regional landscape of the animal vaccines market is marked by distinct geographic trends that reflect variations in economic development, regulatory environments, and consumer preferences. The Americas remain a robust market characterized by high investment in advanced biotechnologies and a proactive approach to animal health. Nations in this region have embraced innovation through substantial funding and supportive governmental policies, which in turn have fostered a dynamic environment for vaccine research and development.

In Europe, the Middle East, and Africa, there is an increasing focus on integrating modern manufacturing techniques with traditional vaccination approaches. This region is witnessing a blend of mature markets with emerging economies where modernization is gradually expanding the scope of animal health initiatives. Stakeholders are focusing on strengthening supply chains, establishing quality control measures, and leveraging regional partnerships to improve access to state-of-the-art vaccine products. These efforts are particularly significant in light of rising concerns around zoonotic diseases and the imperative for stringent health monitoring of livestock populations.

Asia-Pacific represents a rapidly evolving market driven by population growth, urbanization, and rising incomes. This region has seen a surge in demand for advanced vaccines, primarily driven by the expanding livestock sector and the growing popularity of companion animals. Significant investments in research and a burgeoning biopharmaceutical industry are fueling the adoption of innovative vaccine technologies. The interplay between traditional agricultural practices and modern health management strategies in this region is not only boosting vaccine uptake but is also creating new opportunities for market entrants. The regional analysis highlights variations in regulatory frameworks and investment trends, which underscore the importance of tailoring strategic initiatives to local contexts for sustained market growth.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New Jersey, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Strategic Key Companies in the Sector

The competitive landscape in the animal vaccines market is defined by the contributions of several leading companies that are actively shaping trends through innovation and strategic collaborations. Prominent industry players such as Biogenesis Bago S.A. and BioVaxys Technology Corporation have carved out significant market positions by focusing on research-driven approaches and comprehensive solutions that cater to both companion and livestock animal segments. Companies like Boehringer Ingelheim International GmbH and Brilliant Bio Pharma Private Limited continue to define the cutting edge of clinical development with their robust portfolio of vaccine offerings.

Other influential organizations, including Ceva Sante Animale and China Animal Husbandry Industry Co., Ltd., have made substantial inroads in emerging markets by leveraging local expertise and agile manufacturing processes. Dalan Animal Health and Elanco Animal Health Inc. further exemplify the trend towards integrated solutions that merge innovative vaccine technologies with efficient distribution networks. Additionally, firms such as Endovac Animal Health LLC by Immvac Inc. and Hester Biosciences Limited are pushing the boundaries by harnessing novel biotechnology platforms to address emerging pathogens.

Companies like HIPRA, S.A. and Indian Immunologicals Limited are playing pivotal roles in expanding market reach and enhancing vaccine efficacy through targeted research initiatives. The strategic moves from Kemin Industries, Inc. and Merck KGaA have underscored the importance of global partnerships, while Neogen Corporation and Phibro Animal Health Corporation have further expanded their influence through targeted acquisitions and market-specific adaptations. SAN Vet Holding GmbH, Sanofi S.A., and Seppic S.A. stand out for their commitment to continuous innovation, even as Torigen Pharmaceuticals Inc., Vaxxinova GmbH, and VEROVACCiNES GmbH consolidate their presence through specialized product lines. These trends are complemented by the focused efforts of Vetigenics LLC, Vetoquinol SA, Virbac, Inc., and Zoetis Inc., whose diverse strategies emphasize targeted research, agile manufacturing, and an unwavering commitment to improving animal health on a global scale. Their contributions not only drive market innovation but also emphasize a commitment to quality, efficacy, and global health standards.

The report delves into recent significant developments in the Animal Vaccines Market, highlighting leading vendors and their innovative profiles. These include Biogenesis Bago S.A., BioVaxys Technology Corporation, Boehringer Ingelheim International GmbH, Brilliant Bio Pharma Private limited, Ceva Sante Animale, China Animal Husbandry Industry Co., Ltd., Dalan Animal Health, Elanco Animal Health Inc., Endovac Animal Health, LLC by Immvac Inc., Hester Biosciences Limited, HIPRA, S.A., Indian Immunologicals Limited, Kemin Industries, Inc., Merck KGaA, Neogen Corporation, Phibro Animal Health Corporation, SAN Vet Holding GmbH, Sanofi S.A., Seppic S.A., Torigen Pharmaceuticals Inc., Vaxxinova GmbH, VEROVACCiNES GmbH, Vetigenics, LLC, Vetoquinol SA, Virbac, Inc., and Zoetis Inc.. Actionable Recommendations for Industry Leaders

For industry leaders operating in the animal vaccines market, several actionable recommendations are emerging from this comprehensive analysis. First, it is imperative to invest strategically in research and development initiatives that embrace novel vaccine technologies such as mRNA and recombinant platforms. Emphasizing collaborative studies with research institutions and leveraging digital health solutions can streamline development timelines and enhance vaccine efficacy. Capitalizing on data analytics to monitor post-market performance will also support targeted improvements in existing formulations.

Furthermore, strategic portfolio diversification across various product types addresses the distinct needs of both companion and livestock animals. Companies should consider integrating product development strategies that align with comprehensive disease coverage, ranging from bacterial to viral infections. Such diversification not only mitigates risk but also offers new revenue streams by addressing niche market demands.

Enhancing the efficiency of vaccine delivery channels is another key recommendation. Whether deploying injectable vaccines across intramuscular, intravenous, and subcutaneous routes or optimizing oral vaccine formulations, focusing on logistical and clinical efficiencies remains critical. In addition, refining distribution strategies across online platforms, retail pharmacies, and veterinary clinics can improve market penetration and consumer accessibility.

Finally, maintain adaptable regulatory and market strategies that respond dynamically to global trends. This includes proactive engagement with regulatory authorities to ensure alignment with evolving standards, especially in regions with rapidly changing market conditions. By fostering strategic alliances and pursuing regional customization of products and services, industry leaders can better position their organizations to capitalize on emerging opportunities and navigate the complexities of a dynamic global marketplace.

Conclusion and Future Outlook

In conclusion, the animal vaccines market is undergoing a period of significant transformation that is being shaped by technological innovation, strategic segmentation, and dynamic regional factors. This evolving landscape presents both challenges and opportunities that require industry stakeholders to be agile, forward-thinking, and committed to continuous improvement. The in-depth analysis presented herein highlights the importance of embracing novel vaccine platforms and integrating nuanced insights from product, animal type, and disease segmentation to create targeted, effective solutions.

Looking forward, the drive towards digital health integration, coupled with an increased focus on regulatory compliance and strategic global partnerships, will define the pathway for sustained growth and innovation. The synthesis of these industry trends not only affirms the critical role of animal vaccines in achieving improved animal health outcomes but also underscores the broader implications for food safety, public health, and economic development. As decision-makers recalibrate their strategies, the insights provided in this report offer a robust foundation for navigating a complex but promising market landscape.

The future of animal vaccines is bright, bolstered by continuous advancements in technology and science. Stakeholders must remain vigilant and responsive to emerging trends, ensuring that their strategic initiatives are backed by rigorous research and a deep understanding of regional market dynamics. This commitment to adaptive and innovative practices will be the key to unlocking new opportunities and sustaining long-term success in the animal vaccines sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of zoonotic diseases worldwide
      • 5.1.1.2. Government initiatives promoting animal health care globally
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with the R&D and production of animal vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging partnerships with wildlife conservation organizations
      • 5.1.3.2. Innovations in vaccine delivery methods enhancing administration and improving animal immune responses
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations and approval processes associated with animal vaccines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing preference for attenuated live vaccines to protect against diseases with complex pathogen biology
    • 5.2.2. Animal Type: Rising significance of animal vaccines for companion animals owing to increasing pet ownership
    • 5.2.3. Disease Type: Increasing need for animal vaccines to deal with viral infections
    • 5.2.4. Route of Administration: Rising importance of IM vaccines owing to their quick absorption into the bloodstream
    • 5.2.5. Distribution Channel: Increasing preference for online pharmacies owing to growing adoption of digital platforms and convenience
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Animal Vaccines Market, by Product

  • 6.1. Introduction
  • 6.2. Inactivated Vaccines
  • 6.3. Live Attenuated Vaccines
  • 6.4. mRNA Vaccines
  • 6.5. Recombinant Vaccines
  • 6.6. Subunit Vaccines

7. Animal Vaccines Market, by Animal Type

  • 7.1. Introduction
  • 7.2. Companion Animals
    • 7.2.1. Cats
    • 7.2.2. Dogs
  • 7.3. Livestock Animals
    • 7.3.1. Cattle
    • 7.3.2. Poultry
    • 7.3.3. Sheep
    • 7.3.4. Swine

8. Animal Vaccines Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Bacterial Infections
    • 8.2.1. Clostridial
    • 8.2.2. E. Coli
    • 8.2.3. Leptospirosis
    • 8.2.4. Pasteurella
  • 8.3. Fungal Infections
  • 8.4. Parasitic Infections
    • 8.4.1. Ectoparasites
    • 8.4.2. Endoparasites
  • 8.5. Viral Infections
    • 8.5.1. Avian Influenza Virus
    • 8.5.2. Bovine Viral Diarrhea Virus (BVDV)
    • 8.5.3. Foot-and-Mouth Disease Virus (FMDV)
    • 8.5.4. Newcastle Disease Virus
    • 8.5.5. Porcine Reproductive & Respiratory Syndrome Virus (PRRSV)
    • 8.5.6. Rabies Virus

9. Animal Vaccines Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Injectable Vaccines
    • 9.2.1. Intramuscular (IM)
    • 9.2.2. Intravenous (IV)
    • 9.2.3. Subcutaneous (SC)
  • 9.3. Oral Vaccines

10. Animal Vaccines Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies
  • 10.4. Veterinary Clinics

11. Americas Animal Vaccines Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Animal Vaccines Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Animal Vaccines Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Anivive secures USD 20 million investment from Leonid Capital Partners to develop the next generation of pet health
    • 14.3.2. Boehringer Ingelheim unveils next-gen vaccine in India, tackling rising Marek's disease challenges
    • 14.3.3. BioVaxys and SpayVac expand vaccine production to advance wildlife contraception and aquaculture solutions
    • 14.3.4. Ceva Animal Health expands vaccine production with new Hungarian facility
    • 14.3.5. Merck Animal Health unveils RNA-particle feline vaccine to target feline leukemia virus
    • 14.3.6. Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
    • 14.3.7. University of Missouri's innovative vaccine offers new hope against bovine anaplasmosis
    • 14.3.8. ICAR-CIBA and Indian Immunologicals Limited entered into an agreement for commercial development of fish vaccine
    • 14.3.9. Fischer MV partners with BAV to launch livestock and aquaculture vaccines in India
    • 14.3.10. Merck Animal Health's strategic acquisition of Elanco's aqua business enhances vaccine and treatment portfolio in aquaculture sector
    • 14.3.11. Huvepharma's EUR 72 million investment in Bulgarian veterinary vaccine plant to enhance global supply chain
    • 14.3.12. Pioneering partnership enhances African swine fever vaccine development for global pig protection
    • 14.3.13. Zoetis invests AUD 350 million to amplify vaccine production in Australia, bolstering animal health and industry collaboration
    • 14.3.14. Virbac's strategic acquisition of Sasaeah boosts its market position and innovation in Japan's animal vaccine market
    • 14.3.15. Zendal and CSIC introduce innovative DNA vaccine to combat leishmaniasis
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Virbac, Inc.
    • 14.4.2. Phibro Animal Health Corporation
    • 14.4.3. Ceva Sante Animale
    • 14.4.4. Boehringer Ingelheim International GmbH

Companies Mentioned

  • 1. Biogenesis Bago S.A.
  • 2. BioVaxys Technology Corporation
  • 3. Boehringer Ingelheim International GmbH
  • 4. Brilliant Bio Pharma Private limited
  • 5. Ceva Sante Animale
  • 6. China Animal Husbandry Industry Co., Ltd.
  • 7. Dalan Animal Health
  • 8. Elanco Animal Health Inc.
  • 9. Endovac Animal Health, LLC by Immvac Inc.
  • 10. Hester Biosciences Limited
  • 11. HIPRA, S.A.
  • 12. Indian Immunologicals Limited
  • 13. Kemin Industries, Inc.
  • 14. Merck KGaA
  • 15. Neogen Corporation
  • 16. Phibro Animal Health Corporation
  • 17. SAN Vet Holding GmbH
  • 18. Sanofi S.A.
  • 19. Seppic S.A.
  • 20. Torigen Pharmaceuticals Inc.
  • 21. Vaxxinova GmbH
  • 22. VEROVACCiNES GmbH
  • 23. Vetigenics, LLC
  • 24. Vetoquinol SA
  • 25. Virbac, Inc.
  • 26. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. ANIMAL VACCINES MARKET MULTI-CURRENCY
  • FIGURE 2. ANIMAL VACCINES MARKET MULTI-LANGUAGE
  • FIGURE 3. ANIMAL VACCINES MARKET RESEARCH PROCESS
  • FIGURE 4. ANIMAL VACCINES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ANIMAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. ANIMAL VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. ANIMAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANIMAL VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANIMAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANIMAL VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL VACCINES MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SHEEP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SWINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL VACCINES MARKET SIZE, BY E. COLI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PASTEURELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ECTOPARASITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ENDOPARASITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RABIES VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAMUSCULAR (IM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBCUTANEOUS (SC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ORAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. INDIA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. INDONESIA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. INDONESIA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. INDONESIA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. JAPAN ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. JAPAN ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. JAPAN ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 185. JAPAN ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. JAPAN ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 196. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 197. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 200. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 202. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 207. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 208. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 209. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 211. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 218. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 219. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 220. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 222. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 224. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 229. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 230. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 231. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 233. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. TAIWAN ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 235. TAIWAN ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. TAIWAN ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 240. TAIWAN ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 241. TAIWAN ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 242. TAIWAN ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. TAIWAN ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 244. TAIWAN ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 245. THAILAND ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 246. THAILAND ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. THAILAND ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 248. THAILAND ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 249. THAILAND ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. THAILAND ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 251. THAILAND ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 252. THAILAND ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 253. THAILAND ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. THAILAND ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 255. THAILAND ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. VIETNAM ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 257. VIETNAM ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. VIETNAM ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 259. VIETNAM ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 260. VIETNAM ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. VIETNAM ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 262. VIETNAM ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 263. VIETNAM ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 264. VIETNAM ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. VIETNAM ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 266. VIETNAM ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 279. DENMARK ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 280. DENMARK ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. DENMARK ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 282. DENMARK ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 283. DENMARK ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. DENMARK ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 285. DENMARK ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 286. DENMARK ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 287. DENMARK ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 288. DENMARK ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 289. DENMARK ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 290. EGYPT ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 291. EGYPT ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. EGYPT ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 293. EGYPT ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 294. EGYPT ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. EGYPT ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 296. EGYPT ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 297. EGYPT ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 298. EGYPT ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 299. EGYPT ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 300. EGYPT ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 301. FINLAND ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 302. FINLAND ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. FINLAND ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 304. FINLAND ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 305. FINLAND ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. FINLAND ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 307. FINLAND ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 308. FINLAND ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 309. FINLAND ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 310. FINLAND ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 311. FINLAND ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 312. FRANCE ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 313. FRANCE ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. FRANCE ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 315. FRANCE ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 316. FRANCE ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. FRANCE ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 318. FRANCE ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 319. FRANCE ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 320. FRANCE ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 321. FRANCE ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 322. FRANCE ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 323. GERMANY ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 324. GERMANY ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. GERMANY ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 326. GERMANY ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 327. GERMANY ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. GERMANY ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 329. GERMANY ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 330. GERMANY ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 331. GERMANY ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 332. GERMANY ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 333. GERMANY ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 334. ISRAEL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 335. ISRAEL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. ISRAEL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 337. ISRAEL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 338. ISRAEL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 339. ISRAEL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 340. ISRAEL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 341. ISRAEL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 342. ISRAEL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 343. ISRAEL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 344. ISRAEL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 345. ITALY ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 346. ITALY